AIM ImmunoTech Announces Abstract Entitled, Negative Impact of Paclitaxel on Human Breast Tumor Microenvironment and Its Reversal by the Combination of Interferon-α with TLR3 Agonist Rintatolimod, (Ampligen®), Accepted for Poster Presentation by Roswell Park Comprehensive Cancer Center at the AACR 2022 Annual Meeting
OCALA, Fla., March 24, 2022 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM”…
iHerb Expands Consumer Benefits Across Asia with 618 Shopping Festival
Trade Compliance Records Addresses June 2026 Executive Order Broker Liability
Yuno Provides Corporate Update as It Advances Toward Launch, Expands Leadership Team with Talent from Binance, and Positions for Global Prediction Market Growth
Central Asia visit drives multi-sector collaboration, Business delegation signed 66 MoUs and agreements to seize Belt and Road opportunities
Custom Health Holdings Inc. Announces Completion of Plan of Arrangement